628 Views | 548 Downloads
Address for correspondence: Carlos G. Grijalva, Department of Health Policy, Vanderbilt University School of Medicine, 2600 Village at Vanderbilt, 1500 21st Ave, Nashville, TN, USA, 37212; email: Carlos.grijalva@vanderbilt.edu.
For acknowledgments, please see the full article.
C.G.G. has served as a consultant to Pfizer in unrelated work. M.R.G. receives grant funding from MedImmune. K.M.E. receives grant funding from Novartis in unrelated work. J.V.W. serves on a Scientific Advisory Board for Quidel and an Independent Data Monitoring Committee for GlaxoSmithKline, neither related to the present work. C.F.L. serves as a Scientific Advisor to Takeda and GlaxoSmithKline in subjects not related to the present work.
This work was funded by a Vanderbilt University Clinical and Translational Science Award (grant UL1 RR024975) from the National Institutes of Health; an investigator-initiated research grant from Pfizer (IIR WS1898786 [0887X1-4492] to C.G.G. and IIR WS2079099 to J.E.V.); the Thrasher Research Fund (grant 02832-9 to C.G.G.); and a Thrasher Early Career Award (to L.M.H.).
Emerging Infectious Diseases is an open access journal in the public domain. All content is freely available without charge to the user or his/her institution. In accordance with the Budapest Open Access Initiative definition of Open Access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Emerging Infectious Diseases does request a proper citation be included for its content and that any user indicate clearly if changes have been made.